glp-1 weight loss chappaqua NutraPep Support Probiotic Supplement Let’s bust a common myth

In Q1 2025, 24% of patients with both diabetes/obesity and OSA initiated a GLP-1 therapy within six months of diagnosis, compared to 18% of patients with diabetes/obesity alone

Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure

But I think one is that, you know, I learned from my long Covid experience, even how internally ableist I was, and I think ableism and weight ism or whatever, you know, like people not looking optimally healthy, whatever that means, actually sometimes pushes people to do things that are less actually healthy but look healthier, you know

24(8): p

They should be considered superior in most patients, including those with HF and CKD.3 However, ischaemia prevention is superior for GLP-1 RAs, thus making them preferable in patients with predominant ASCVD risk.3 Differences in routes of administration and adverse effect profiles may also play a role in prescription decisions

The IdeaUsher Edge: We take inspiration from platforms like Noom , which uses psychological triggers to build habits